Butylated hydroxytoluene (BHT) improved semen quality and sperm DNA of frozen-thawed Arabian stallions preserved in modified INRA-82 extender.

This study tested different doses of the antioxidant BHT in a common freezing extender for Arabian stallion semen and found that 1.0 mM best protected post‑thaw sperm quality and DNA. Higher doses (2–4 mM) actually worsened semen quality compared with no BHT.

What the researchers asked and why it matters

• Question: Is there an optimal concentration of the lipophilic antioxidant butylated hydroxytoluene (BHT) that improves the quality of frozen‑thawed stallion semen?
• Rationale: Cryopreservation generates reactive oxygen species (ROS) that damage sperm lipids, membranes, acrosomes, and DNA. Lipid‑soluble antioxidants like alpha‑tocopherol (vitamin E) can limit lipid peroxidation; BHT is a synthetic analog with similar ROS‑scavenging actions and membrane protection.
• Clinical/industry relevance: Identifying a dose that preserves motility, membrane integrity, and DNA could improve post‑thaw semen performance for breeding programs using modified INRA‑82 extender.

Study design and methods (as described)

• Samples: Frozen‑thawed semen from Arabian stallions processed in a modified INRA‑82 extender.
• Treatments: Extender was supplemented with BHT at 0.0, 0.25, 0.50, 1.0, 2.0, and 4.0 mM (reported in the abstract as mM/ml; interpreted as millimolar in the extender).
• Post‑thaw assessments:
  • Sperm progressive motility at 0, 1, 2, and 3 hours (to assess immediate quality and short‑term longevity).
  • Viability index (overall live/dead assessment integrating motility/viability measures).
  • Plasma membrane integrity via hypo‑osmotic swelling test (HOST).
  • Acrosome integrity (structural preservation of the acrosomal cap).
  • DNA integrity via comet assay:
    • Non‑fragmented DNA (% intact).
    • % DNA in the comet head (more indicates better integrity) and tail (more indicates more fragmentation).
    • Comet tail length and tail moment (higher values indicate greater DNA damage).
• Statistics: The authors report that 1.0 mM yielded the highest values (significant improvements), while higher doses impaired quality; exact P‑values not fully shown in the abstract.

Key findings

• Optimal dose identified:
  • 1.0 mM BHT produced the best overall post‑thaw profile across measures, including higher progressive motility at 0–3 h, higher viability index, better plasma membrane and acrosome integrity, and improved DNA integrity indices on the comet assay.
• Suboptimal and harmful ranges:
  • Low doses (0.25–0.50 mM) offered limited or smaller benefits than 1.0 mM.
  • High doses (2.0–4.0 mM) deteriorated semen quality compared with the non‑supplemented control, indicating a toxic or pro‑oxidant range.
• DNA protection signal:
  • With 1.0 mM, there was more DNA in the comet head, less in the tail, and reduced tail length and tail moment—consistent with less DNA fragmentation after thawing.
• Bottom line: For modified INRA‑82, 1.0 mM BHT appears to be the optimal concentration for protecting motility, membranes, acrosomes, and DNA in frozen‑thawed Arabian stallion sperm.

How to interpret the biology

• Mechanism of benefit:
  • Equine sperm membranes are rich in polyunsaturated fatty acids and are highly susceptible to lipid peroxidation during cooling and thawing.
  • BHT, a lipophilic antioxidant, partitions into the membrane, scavenges lipid peroxyl radicals, and interrupts chain reactions that damage membranes and associated structures (including the acrosome).
  • By limiting oxidative damage, BHT helps preserve motility machinery and maintains DNA integrity, reflected by improved comet assay metrics.
• Why too much is harmful:
  • Excess antioxidant can act as a pro‑oxidant in some contexts or disrupt membrane biophysics.
  • Over‑suppression of ROS may impair physiological signaling required for motility and capacitation‑related processes.
  • High concentrations of lipophilic molecules can destabilize membranes or introduce solvent effects, reducing sperm function.

Practical implications for breeding centers

• When using modified INRA‑82 for Arabian stallions:
  • Target BHT at 1.0 mM in the extender for cryopreservation.
  • Avoid concentrations ≥2.0 mM, which are associated with poorer outcomes than no BHT.
  • Expect improvements not only in immediate post‑thaw motility but also in short‑term motility retention (up to 3 hours) and DNA integrity.
• Implementation notes:
  • Confirm the solvent and preparation protocol for BHT to ensure accurate dosing and sperm‑safe vehicle concentrations.
  • Validate the 1.0 mM setting in your own lab with stallion‑specific testing, as individual variability can influence responses.
  • Use objective motility and membrane assays to monitor outcomes after adoption.
• Fertility outcomes:
  • The study did not report pregnancy or foaling rates; while lab metrics generally correlate with fertility, field trials are needed to confirm reproductive benefits.

Strengths and limitations

• Strengths:
  • Systematic dose–response testing spanning sub‑, optimal, and supra‑physiological ranges.
  • Comprehensive quality panel including motility, membrane and acrosome integrity, and DNA fragmentation (comet assay), giving a multidimensional picture.
• Limitations:
  • Details on sample size, number of stallions/ejaculates, and statistical outputs are not provided in the abstract.
  • Findings are specific to Arabian stallions and a modified INRA‑82 extender; generalizability to other breeds or extenders requires testing.
  • Fertility endpoints (insemination success) were not assessed.
  • Potential confounders such as the BHT solvent, ROS levels, or lipid peroxidation markers (e.g., MDA) were not reported here.

How this fits with prior work

• Concordant with antioxidant literature:
  • Echoes prior reports that lipophilic antioxidants (e.g., alpha‑tocopherol) can protect cryopreserved sperm yet have a narrow therapeutic window.
  • Reinforces the principle that optimal, not maximal, antioxidant dosing is critical; supra‑optimal concentrations can be detrimental.

Recommendations and next research steps

• Recommendations for practice:
  • Adopt 1.0 mM BHT in modified INRA‑82 for Arabian stallion semen, with local validation.
  • Implement quality control using motility time‑courses, HOST, acrosome assays, and (where feasible) DNA integrity testing.
• Research priorities:
  • Refine the dose window (e.g., 0.75–1.25 mM) and assess interactions with other antioxidants (vitamin E, catalase, SOD).
  • Test across breeds, individual stallions, and different extenders to assess generalizability.
  • Link lab outcomes to fertility metrics (pregnancy, foaling rates) in controlled AI trials.
  • Measure mechanistic markers (ROS levels, lipid peroxidation indices) to confirm modes of action and toxicity at higher doses.
  • Evaluate long‑term storage effects and post‑thaw longevity beyond 3 hours under field‑relevant conditions.

Take‑home messages

• There is a clear optimal dose of BHT for equine semen cryopreservation in modified INRA‑82, centered at 1.0 mM.
• Higher concentrations (≥2.0 mM) undermine sperm quality, highlighting the importance of precise antioxidant dosing.
• Benefits extend to motility, membrane and acrosome integrity, and notably DNA integrity, which may have downstream implications for fertility.